uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Synthetic siRNA targeting human papillomavirus 16 E6: a perspective on in vitro nanotherapeutic approaches
Thunder Bay Reg Hlth Res Inst, Probe Dev & Biomarker Explorat, Thunder Bay, ON, Canada; Lakehead Univ, Biotechnol Program, Thunder Bay, ON, Canada.
Thunder Bay Reg Hlth Res Inst, Probe Dev & Biomarker Explorat, Thunder Bay, ON, Canada; Lakehead Univ, Biotechnol Program, Thunder Bay, ON, Canada.
Thunder Bay Reg Hlth Res Inst, Probe Dev & Biomarker Explorat, Thunder Bay, ON, Canada; UHN, Michener Inst Educ, Genet Technol Program, Toronto, ON, Canada.
Thunder Bay Reg Hlth Res Inst, Probe Dev & Biomarker Explorat, Thunder Bay, ON, Canada; Lakehead Univ, Dept Biol, Thunder Bay, ON, Canada.
Show others and affiliations
2018 (English)In: Nanomedicine, ISSN 1743-5889, E-ISSN 1748-6963, Vol. 13, no 4, p. 455-474Article in journal, Editorial material (Other academic) Published
Abstract [en]

High-risk human papillomaviruses infect skin and mucosa, causing approximately 5% of cancers worldwide. In the search for targeted nanotherapeutic approaches, siRNAs against the viral E6 transcript have been molecules of interest but have not yet seen successful translation into the clinic. By reviewing the past approximately 15 years of in vitro literature, we identify the need for siRNA validation protocols which concurrently evaluate ranges of key treatment parameters as well as characterize downstream process restoration in a methodical, quantitative manner and demonstrate their implementation using our own data. We also reflect on the future need for more appropriate cell culture models to represent patient lesions as well as the application of personalized approaches to identify optimal treatment strategies.

Place, publisher, year, edition, pages
2018. Vol. 13, no 4, p. 455-474
Keywords [en]
cell culture models, cervical cancer, dicer substrate siRNA, E6 oncogene, human papillomavirus 16, RNA interference, siRNA, siRNA therapy
National Category
Medical Biotechnology (with a focus on Cell Biology (including Stem Cell Biology), Molecular Biology, Microbiology, Biochemistry or Biopharmacy)
Identifiers
URN: urn:nbn:se:uu:diva-355835DOI: 10.2217/nnm-2017-0242ISI: 000427394600007PubMedID: 29382252OAI: oai:DiVA.org:uu-355835DiVA, id: diva2:1231497
Available from: 2018-07-06 Created: 2018-07-06 Last updated: 2018-07-06Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMed

Authority records BETA

Chattopadhyaya, Jyoti

Search in DiVA

By author/editor
Chattopadhyaya, Jyoti
By organisation
Molecular Biology
In the same journal
Nanomedicine
Medical Biotechnology (with a focus on Cell Biology (including Stem Cell Biology), Molecular Biology, Microbiology, Biochemistry or Biopharmacy)

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 58 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf